Form 4: UroGen Pharma Executive Sells Shares
Insider Transaction (Form 4)
Jason Drew Smith, General Counsel of UroGen Pharma Ltd., sold 1,519 shares of common stock on September 7, 2026 for $42.54 per share.
Summary
- Option exercise/conversion: acquired 3,334 Ordinary Shares on September 7, 2026; holds 54,660 after (Direct).
- Open-market sale: disposed of 1,519 Ordinary Shares at $42.54 ($64,618) on September 8, 2026; holds 53,141 after (Direct).
- Option exercise/conversion: disposed of 3,334 Restricted Stock Units on September 7, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $64,618 of stock on the open market.
Insider Transactions
Jason Drew Smith — Officer (General Counsel)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-07 | Option exercise/conversion | Ordinary Shares | 3,334 | — | — | 54,660 |
| 2026-09-08 | Open-market sale | Ordinary Shares | 1,519 | $43 | $64.6K | 53,141 |
| 2026-09-07 | Option exercise/conversion | Restricted Stock Units | 3,334 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-07 | Option exercise/conversion (3,334 shares) |
| 2026-09-08 | Open-market sale (1,519 shares) |
| 2026-09-07 | Option exercise/conversion (3,334 shares) |
Keywords
insider transaction, Form 4, URGN, UroGen Pharma Ltd., bearish, Jason Drew Smith
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.